Labcorp and CHOP Partner to Scale Pediatric Diagnostic Testing Nationwide

Event summary

  • Labcorp and Children's Hospital of Philadelphia (CHOP) announced a strategic collaboration on April 13, 2026, to accelerate the development and nationwide availability of specialized pediatric diagnostics.
  • The partnership combines CHOP's pediatric research and clinical expertise with Labcorp's national diagnostic infrastructure and commercialization capabilities.
  • The collaboration aims to streamline the path from discovery to national availability for pediatric-specific diagnostics, focusing on areas such as oncology, metabolic disease, and autoimmune conditions.
  • Labcorp's nearly 71,000 employees serve clients in approximately 100 countries, supporting over 85% of new drugs approved by the FDA in 2025.

The big picture

This collaboration addresses a critical gap in pediatric healthcare, where traditional adult-oriented diagnostics often fail to account for children's unique biology. By leveraging Labcorp's national reach and CHOP's pediatric expertise, the partnership aims to bring more accurate and timely diagnostic solutions to a broader patient base. The move reflects a broader industry trend toward specialized diagnostics tailored to specific patient demographics, driven by advancements in genetic and metabolic testing.

What we're watching

Pipeline Efficiency
How the joint innovation pipeline will affect the speed of bringing new pediatric diagnostics to market.
Market Expansion
Whether the collaboration can significantly expand access to advanced pediatric testing across the U.S.
Regulatory Compliance
The pace at which the partnership can navigate regulatory hurdles for new diagnostic tests.

Related topics

Diagnostics